HETEROCYCLICETHENEDIYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE
申请人:RORER INTERNATIONAL (HOLDINGS)
公开号:EP0527181A1
公开(公告)日:1993-02-17
EP0527181A4
申请人:——
公开号:EP0527181A4
公开(公告)日:1993-04-07
US5196446A
申请人:——
公开号:US5196446A
公开(公告)日:1993-03-23
[EN] HETEROCYCLICETHENEDIYL COMPOUNDS WHICH INHIBIT EGF RECEPTOR TYROSINE KINASE
申请人:RHONE-POULENC RORER INTERNATIONAL (HOLDINGS), INC.
公开号:WO1991016305A1
公开(公告)日:1991-10-31
(EN) Heteroarylethenediyl or heteroarylethenediyl aryl compounds wherein the heteroaryl group can be mono- or bicyclic heteroaryl and the aryl group can be mono- or bicyclic heteroaryl or bi- or tricyclic carbocyclic, said compound optionally substituted or polysubstituted, with the proviso that the heteroaryl group is not furyl or thienyl when the ethenediyl group has geminal cyano substituents, and pharmaceutical compositions comprising said compounds, and the use thereof for inhibiting cell proliferation in a patient suffering from such disorder.(FR) Des composés hétéroaryléthènediyle ou hétéroaryléthènediyle aryle dans lesquels le groupe hétéroaryle peut être un hétéroaryle monocyclique ou bicyclique et le groupe aryle peut être hétéroaryle monocyclique ou bicyclique ou carbocyclique bicyclique ou tricyclique, ledit composé étant éventuellement substitué ou polysubstitué, à condition que le groupe hétéroaryle ne soit pas furyle ou thiényle lorsque le groupe éthènediyle possède des substituants cyano géminés, et des compositions pharmaceutiques comprenant ces composés, et leur utilisation pour inhiber la prolifération de cellules chez un patient souffrant de cette maladie.
Certain indole compounds which inhibit EGF receptor tyrosine kinase
申请人:Yissum Research Development Company of the Hebrew University of Jerusalem
公开号:US05196446A1
公开(公告)日:1993-03-23
Heteroarylethenediyl compounds wherein the heteroaryl group can be mono- or icyclic heteroaryl and the aryl group can be or mono- or bicyclic carbocyclic, said compound optionally substituted or polysubstituted, with the proviso that the heteroaryl group is not furyl or thienyl when the ethenediyl group has geminal cyano substituents, and pharmaceutical compositions comprising said compounds, and the use thereof for inhibiting a protein tyrosine kinase portion of a receptor selected from epidermal growth factor and platelet derived growth factor in a patient suffering from such disorder.